Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich(The University of Western Australia), Thomas Guldager Lauridsen, Hong Yuan(Chinese Academy of Medical Sciences & Peking Union Medical College), Martin Chaumont, Ji‐Guang Wang(Ruijin Hospital), Murray Esler(Baker Heart and Diabetes Institute), George L. Bakris(Pennsylvania State System of Higher Education), Andrew E. Ajani, M Bellet(Idorsia (Switzerland)), Jianjun Mu(First Affiliated Hospital of Xi'an Jiaotong University), Ivor Katz(St George Hospital), Grahame J. Elder, Thomas Vanassche, Jianhong Xie, Ginette Girard, Martin Ullrych, J Widimský(Institute for Postgraduate Medical Education), Roland F. Dreier(Idorsia (Switzerland)), Fatima Merali, Alexandre Persu(Cliniques Universitaires Saint-Luc), John M. Flack(Southern Illinois University School of Medicine), Michael A. Weber(SUNY Downstate Health Sciences University), Ernesto L. Schiffrin(Jewish General Hospital), Ivan Rychlík, George K. Dresser(American Heart Association), Yingqing Feng(Jinan University), Lloyd Haskell(Johnson & Johnson (United States)), Christopher M. Reid(The University of Melbourne), Mouna Sassi-Sayadi(Idorsia (Switzerland)), Renata Cífková(Brigham and Women's Hospital), John G. Mooney(Southern Illinois University School of Medicine), Tine De Backer, J. Václavík(University of Ostrava), Lew Pliamm, Sinjini Biswas, Parisa Danaietash(Idorsia (Switzerland)), Shivinder Jolly, Jean-Marie Krzesinski, Miroslav Souček, Krzysztof Narkiewicz(Gdańsk Medical University), Ling Lin, Jing Yu(Zhejiang University of Technology), Simon D. Roger(Gosford Hospital), S. P. Chow(Cornell University), David Colquhoun, Michel Vallée, Xin Zhang(Southwest Petroleum University), Martin Lukáč
The Lancet
November 7, 2022
Cited by 223


Related Papers